WEBINAR

This page is Eco Friendly
Catholic Laparoscopic Advanced Surgery School
OB&GYN
BRCA awareness in 2020 - Molipharma

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Largo A. Gemelli, 8 Roma

           Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica

BRCA Awareness in 2020

Webinar November 13th, 2020
FAD available from November 13th, 2020 to May 13th, 2021

Rome

DIRETTORE DELLA SCUOLA CLASS:
Prof. Giovanni Scambia
, Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

DIRETTORE DEL CORSO:
Prof.ssa Anna Fagotti, Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

RESPONSABILI SCIENTIFICI:
Dott.ssa Claudia Marchetti
, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS;
Dott.ssa Antonella Pietragalla,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

FACULTY

Campanella Ornella
IRCCS ISMETT srl- Istituto Mediterraneo per i trapianti e terapie ad alta specializzazione- Palermo

Fagotti Anna
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Fruscio Robert
Università degli Studi di Milano-Bicocca; ASST Monza – San Gerardo Hospital

Genuardi Maurizio
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Manchanda Ranjit
Wolfson Institute of Preventive Medicine, Barts Cancer Research UK Centre, Queen Mary University of London

Marchetti Claudia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Minucci Angelo
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Paris Ida
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Pietragalla Antonella
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Salutari Vanda
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Steenbeek Miranda
Radboud university medical centre Nijmegen, the Netherlands

Scambia Giovanni
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Testa Antonia Carla
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

AIM

Deleterious mutations in DNA repair pathways, including breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 (BRCA2) mutation carries, predispose to an elevated risk for several familial tumor types, such as ovarian cancer (OC), breast cancer and prostate cancer.

In this scenario, due to its poor prognosis, OC management remains a major clinical problem and an in-depth analysis of the genomic landscape has gained a growing importance in the last few years. Women who carry a BRCA 1/2 mutation have long been known to present a substantial increased lifetime risk of OC development. Currently, several OC screening programs, including a detailed family history, clinical examination, transvaginal ultrasound and/or serum CA-125 on an annual basis, have been proposed and might be able to reduce OC incidence and mortality in this setting of patients [5]. The aim is to identify women population that could benefit from screening program as a means of early detention and possible prevention of advanced-stage disease. Available literature data do not support a definitive ovarian screening recommendation and the the lack of consistent screening methods of early OC detection, as well as the poor OC prognosis mentioned above, have worldwide elected the risk-reducing surgery as the most effective prophylactic measure for reducing OC risk in BRCA carries [6], [7]. This approach has raised many questions, especially on several aspects of health and patient’s quality of life (QoL).

This conference provides highlights in current risk-reducing OC strategies to potentially suggest a more tailored treatment approach in patients with BRCA1 and/or BRCA2 mutations.

SCIENTIFIC PROGRAM

10.00      Introduction

10.20      Current guidelines of Brca testing, Maurizio Genuardi

10.40      Pros and Cons of Universal Screening of Women for BRCA Mutations, Ranjit Manchanda

11.00      Risk Reducing options, Claudia Marchetti

11.20      Opportunistic salpingectomy and delayed oophorectomy. Evidences and prospectives, Miranda Steenbeek 

11.40      Results from SOLO-trials and PAOLA-1, Vanda Salutari

12.00      Brca-related cancers other than Ovary. How should we prevent? Ida Paris

12.20      Genetic Counselling: physician & patient’s prospective, Antonella Pietragalla, Ornella Campanella

12.40      Discussion, All

13.00      Break

14.00      Somatic or germline BRCA/HRD assessment: differences and interpretation, Angelo Minucci

14.20      BRCA Registry Project (sponsored by SIGO): which efforts, which expectations? Robert Fruscio

14.40      BRCA radiologic assessment: something different? Antonia Carla Testa

15.00      BRCA UNIT: our proposal, Giovanni Scambia

15.20      Discussion and Closing Remarks, All

CREDITI FORMATIVI

Sono stati attribuiti n. 4 crediti ECM per le seguenti categorie:

  • MEDICO CHIRURGO
    • Discipline: GENETICA MEDICA; GINECOLOGIA ED OSTETRICIA; ONCOLOGIA

REGISTRATIONE

La registrazione può essere effettuata collegandosi al sito www.obegyn.com

L’iscrizione al corso è gratuita

La conferma di avvenuta ammissione al corso dovrà pervenire, via e-mail,  dalla segreteria Molipharma (info@molipharma.com), successivamente alla compilazione della scheda di registrazione.

I

PROVIDER

Via Ravenna, 9C 00161 –  Roma (Italy)
Tel +39 06 83393669   Fax +39 06 89283835
Web: www.medical-net.it
accreditato dalla Commissione Nazionale ECM  n° 256

LOCAL SECRETARIAT

Molipharma s.r.l.

E-mail: info@molipharma.com

Phone number: +39 06 30156014

Con il contributo non condizionante di: